Clinical trials of new drugs for the treatment of rheumatoid arthritis: Focus on early disease

Annals of the Rheumatic Diseases

Volumn 75, Issue 7, 2016, Pages 1268-1271

  Smolen, Josef S ^a   Basset, Sabine Collaud ^b   Boers, Maarten ^c,d   Breedveld, Ferdinand ^e   Edwards, Christopher J ^f   Kvien, Tore K ^g   Miossec, Pierre ^h   Tuulikki, Sokka Isler ⁱ   Van Vollenhoven, Ronald F ^c,d,j   Abadie, Eric C ^k,l   Bruyère, Olivier ^m   Cooper, Cyrus ^f,n,o   Mäkinen, Heidi ^p   Thomas, Thierry ^q,r   Tugwell, Peter ^s   Reginster, Jean Yves ^m  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b TRB Chemedica International SA   (Switzerland)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Amsterdam Rheumatology and Immunology Center   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g DIAKONHJEMMET HOSPITAL   (Norway)

^h University of Lyon   (France)

ⁱ UNIVERSITY OF EASTERN FINLAND   (Finland)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k Academic Medical Center ^*  (France)

^l UNIVERSITY OF LISBON   (Portugal)

^m UNIVERSITY OF LIÈGE   (Belgium)

ⁿ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p TAMPERE UNIVERSITY HOSPITAL   (Finland)

^q UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^r UNIVERSITÉ DE LYON   (France)

^s UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; NEW DRUG; ANTIRHEUMATIC AGENT;

ARTICLE; BOOLEAN CRITERIA; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL TRIAL (TOPIC); DAS28; DISEASE ACTIVITY; DISEASE ASSESSMENT; DISEASE DURATION; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; RELIABILITY; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; TOTAL QUALITY MANAGEMENT; TREATMENT INDICATION; ARTHRITIS, RHEUMATOID; EARLY DIAGNOSIS; EUROPE; PRACTICE GUIDELINE; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; EARLY DIAGNOSIS; EUROPE; HUMANS; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84963853014     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209429     Document Type: Article

References (30)

1. European Agency for the Evaluation of Medicinal Products. Guideline on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis. 20 March 2015. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/06/WC500187583.pdf (accessed 22 Jan 2016).
2. Smolen JS, Boers M, Abadie EC, et al. Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1732-6.
3. Smolen JS, Boers M, Abadie EC, et al. Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. Curr Med Res Opin 2011;27:315-25.
4. European Agency for the Evaluation of Medicinal Products. Points to consider on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis. 17 December 2003. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003439.pdf (accessed 22 Jan 2016).
5. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
6. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
7. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73:492-509.
8. European Medicines Agency. Concept paper on the need for revision of the points to consider on the clinical investigation of medicinal products other than NSAIDS in rheumatoid arthritis (CPMP/EWP/556/95 REV. 1). 20 January 2010. http://trbmossge:8801/sites/scientifique/Docs/Documents/E/Conceptpaperneedrevision.pdf (accessed 22 Jan 2016).
9. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1-25.
10. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
11. Felson DT. Whither the ACR20? J Rheumatol 2004;31:835-7.
12. Felson DT, LaValley MP. The ACR20 and defining a threshold for response in rheumatic diseases: Too much of a good thing. Arthritis Res Ther 2014;16:101.
13. Boers M, Kostense PJ. Non-overlapping American College of Rheumatology response rates: A better way to report response in rheumatoid arthritis clinical trials. Arthritis Rheum 2010;62:3524-7.
14. Aletaha D, Martinez-Avila J, Kvien TK, et al. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis 2012;71:1190-6.
15. van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005;64:1582-7.
16. Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71.
17. Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36.
18. Mäkinen H, Kautiainen H, Hannonen P, et al. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005;64: 1410-13.
19. Bakker MF, Jacobs JW, Verstappen SM, et al. Tight control in the treatment of rheumatoid arthritis: Efficacy and feasibility. Ann Rheum Dis 2007;66(Suppl 3): 56-60.
20. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
21. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
22. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50.
23. Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 2016;75:1081-91.
24. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
25. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
26. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
27. Smolen JS, Aletaha D, Gruben D, et al. Remission rates with tofacitinib treatment in rheumatoid arthritis: A comparison of various remission criteria. Arthritis Rheum 2012;64(Suppl 10):S334.
28. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-R806.
29. Pincus T, Furer V, Keystone E, et al. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken) 2011;63: 1142-9.
30. Curtis JR, Churchill M, Kivitz A, et al. A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol. Arthritis Rheumatol 2015;67:3104-12.